Antimicrobial Peptides: Avant-Garde Antifungal Agents to Fight against Medically Important Candida Species

Gina P Rodríguez-Castaño; Frank Rosenau; Ludger Ständker; Carolina Firacative

doi:10.3390/pharmaceutics15030789

Antimicrobial Peptides: Avant-Garde Antifungal Agents to Fight against Medically Important Candida Species

Gina P Rodríguez-Castaño, Frank Rosenau, Ludger Ständker, Carolina Firacative

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Expanding the antifungal drug arsenal for treating Candida infections is crucial in this era of the rising life expectancy of patients with immunosuppression and comorbidities. Infections caused by Candida species are on the rise, including those caused by multidrug-resistant strains or species, and the list of antifungals approved for the treatment of these infections is still limited. Antimicrobial peptides (AMPs) are short cationic polypeptides whose antimicrobial activity is under intense investigation. In this review, we present a comprehensive summary of the AMPs with anti-Candida activity that have undergone successful preclinical or clinical trials. Their source, mode of action, and animal model of infection (or clinical trial) are presented. In addition, as some of these AMPs have been tested in combination therapy, the advantages of this approach, as well as the studied cases that have used AMPs and other drugs concomitantly to fight Candida infections, are described.

Original language	English (US)
Journal	Pharmaceutics
Volume	15
Issue number	3
DOIs	https://doi.org/10.3390/pharmaceutics15030789
State	Published - Feb 27 2023

All Science Journal Classification (ASJC) codes

Microbiology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/pharmaceutics15030789

Cite this

@article{00913c3cd6d94cc2912ca7a40240ff9d,

title = "Antimicrobial Peptides: Avant-Garde Antifungal Agents to Fight against Medically Important Candida Species",

abstract = "Expanding the antifungal drug arsenal for treating Candida infections is crucial in this era of the rising life expectancy of patients with immunosuppression and comorbidities. Infections caused by Candida species are on the rise, including those caused by multidrug-resistant strains or species, and the list of antifungals approved for the treatment of these infections is still limited. Antimicrobial peptides (AMPs) are short cationic polypeptides whose antimicrobial activity is under intense investigation. In this review, we present a comprehensive summary of the AMPs with anti-Candida activity that have undergone successful preclinical or clinical trials. Their source, mode of action, and animal model of infection (or clinical trial) are presented. In addition, as some of these AMPs have been tested in combination therapy, the advantages of this approach, as well as the studied cases that have used AMPs and other drugs concomitantly to fight Candida infections, are described.",

author = "Rodr{\'i}guez-Casta{\~n}o, {Gina P} and Frank Rosenau and Ludger St{\"a}ndker and Carolina Firacative",

year = "2023",

month = feb,

day = "27",

doi = "10.3390/pharmaceutics15030789",

language = "English (US)",

volume = "15",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

TY - JOUR

T1 - Antimicrobial Peptides: Avant-Garde Antifungal Agents to Fight against Medically Important Candida Species

AU - Rodríguez-Castaño, Gina P

AU - Rosenau, Frank

AU - Ständker, Ludger

AU - Firacative, Carolina

PY - 2023/2/27

Y1 - 2023/2/27

N2 - Expanding the antifungal drug arsenal for treating Candida infections is crucial in this era of the rising life expectancy of patients with immunosuppression and comorbidities. Infections caused by Candida species are on the rise, including those caused by multidrug-resistant strains or species, and the list of antifungals approved for the treatment of these infections is still limited. Antimicrobial peptides (AMPs) are short cationic polypeptides whose antimicrobial activity is under intense investigation. In this review, we present a comprehensive summary of the AMPs with anti-Candida activity that have undergone successful preclinical or clinical trials. Their source, mode of action, and animal model of infection (or clinical trial) are presented. In addition, as some of these AMPs have been tested in combination therapy, the advantages of this approach, as well as the studied cases that have used AMPs and other drugs concomitantly to fight Candida infections, are described.

AB - Expanding the antifungal drug arsenal for treating Candida infections is crucial in this era of the rising life expectancy of patients with immunosuppression and comorbidities. Infections caused by Candida species are on the rise, including those caused by multidrug-resistant strains or species, and the list of antifungals approved for the treatment of these infections is still limited. Antimicrobial peptides (AMPs) are short cationic polypeptides whose antimicrobial activity is under intense investigation. In this review, we present a comprehensive summary of the AMPs with anti-Candida activity that have undergone successful preclinical or clinical trials. Their source, mode of action, and animal model of infection (or clinical trial) are presented. In addition, as some of these AMPs have been tested in combination therapy, the advantages of this approach, as well as the studied cases that have used AMPs and other drugs concomitantly to fight Candida infections, are described.

U2 - 10.3390/pharmaceutics15030789

DO - 10.3390/pharmaceutics15030789

M3 - Review article

C2 - 36986650

SN - 1999-4923

VL - 15

JO - Pharmaceutics

JF - Pharmaceutics

IS - 3

ER -

Antimicrobial Peptides: Avant-Garde Antifungal Agents to Fight against Medically Important Candida Species

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Fingerprint

Cite this